Showing 81-85 of 121 real-world data insights & analytics:
Real-World Data and External Control Arms 101

Thu, Apr 29, 2021 11:30 AM – 12:30 PM EDT Register Real-world data is increasingly being used to develop external control arms for trial planning and regulatory submissions. Understanding the basics of what they are and how they can be used effectively are critical to success. Join Dr. Richard Gliklich, CEO of OM1, as he[…]

American Academy Of Dermatology Collaborates With OM1 To Empower More Measured & Precise Care And Treatments For Dermatology

BOSTON, April 8, 2021 /PRNewswire/ — OM1, a real-world outcomes and technology company, today announced a strategic collaboration with the American Academy of Dermatology (AAD) connecting the Academy’s DataDerm™ clinical data registry to OM1’s real-world data and evidence platforms. The AAD estimates that 1 in 4 Americans (more than 85 million) see a physician for[…]

Black Women Less Likely To Undergo Digital Breast Tomosynthesis

M.D. Alert Published: March 5, 2021 Read the Full Commentary >> (Reuters Health) – Women have better screening outcomes with digital breast tomosynthesis, but a new study suggests that Black women have less access to this imaging modality. Researchers examined data on 385,503 women screened at one of 63 U.S. breast imaging facilities between 2015[…]

Outcomes By Race In Breast Cancer Screening With Digital Breast Tomosynthesis Versus Digital Mammography

Journal of the American College of Radiology Published: February 16, 2021 Read the Full Manuscript >> Abstract Purpose Digital breast tomosynthesis (DBT) in conjunction with digital mammography (DM) is becoming the preferred imaging modality for breast cancer screening compared with DM alone, on the basis of improved recall rates (RR) and cancer detection rates (CDRs).[…]